Live Breaking News & Updates on Nmibc

Stay updated with breaking news from Nmibc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Extended Lymphadenectomy Does Not Lead to Survival Benefit in MIBC

Extended lymphadenectomy at the time of radical cystectomy did not produce a significant improvement in disease-free survival (DFS) or overall survival (OS) vs standard lymphadenectomy for patients with muscle-invasive bladder cancer. ....

United States , Baylor College Of Medicine , Sethp Lerner , Baylor College , Extended Lymphadenectomy , Muscle Invasive Bladder Cancer , Swog S1011 Trial ,

FDA Issues Complete Response Letter to BLA for N-803 in BCG-unresponsive NMIBC in Situ

The FDA has issued a complete response letter regarding the biologics license application for N-803 in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. ....

Bacillus Calmette Gu , Bacillus Calmette Guerin , Bacillus Calmette Guérin , N 803 , Complete Response Letter , Non Muscle Invasive Bladder Cancer With Carcinoma In Situ , Non Muscle Invasive Bladder Cancer ,

FDA Grants 501K Clearance to Bladder EpiCheck for Surveillance in NMIBC

The FDA has granted 510K clearance to Bladder EpiCheck for use as a noninvasive method for surveillance of tumor recurrence in previously diagnosed patients with non–muscle invasive bladder cancer, in conjunction with cystoscopy. ....

United States , Eli Frydman , Aharona Shuali , Catholic University Of The Sacred Heart , Affairs At Nucleix , Bladder Epicheck , Medical Affairs , Catholic University , Sacred Heart , 501k Clearance , Non Muscle Invasive Bladder Cancer , Bladder Cancer , Dna Methylation Mrkers , Urine Test , Catholic University Of The Sacred Heart ,

Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC

Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer. ....

United States , Urogen Pharma , Roger Li , Moffitt Cancer Center , American Urological Association Annual Meeting , Bacillus Calmette Gu , Urological Association Annual , Arquer Diagnostics , Phase 2 Core 001 Trial , Non Muscle Invasive Bladder Cancer ,

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage. ....

United States , San Francisco , Development Expenses , Regulation Services Provider , American Urology Association , Company Anti , American Society Of Clinical Oncology , Toronto Stock Exchange Venture , Life Sciences , Technologies Inc , Venture Exchange , Company Photo Dynamic Compounds , Clean Technology , Photo Dynamic Compounds , Consolidated Statements , Canadian Dollars , Muscle Invasive Bladder Cancer , Anti Cancer Therapy , Diversified Industries , Non Brokered Private , Trade Name , Break Through Designation , Study Treatment , Principal Investigator , Evaluable Patients , Indeterminate Response ,